View:
Mini BasicThis view is available after user registration.
ShortThis view is available when you buy a license.
StandardThis view is available when you buy a license.
CompleteThis view is available when you buy a license.
Sacituzumab Govitecan 10 / Pembrolizumab 200, Breast Cancer
Protocol-ID: 3011 V1.0 (Mini), SACGOV10/PEMB200, Breast CaIndication(s)
- Breast Cancer; ICD-10 C50.-
PD-L1+ & tripel negative
Links
- Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. [ASCO Abstracts doi]
 | The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti. |
Valid since: 26.09.2025